Source opening oral regimens: oropharyngeal candidiasis 200 mg once then 100 mg daily; esophageal candidiasis 100 to 200 mg daily up to 400 mg/day; cryptococcal meningitis 400 mg once then 200 mg daily for 10 to 12 weeks, suppression 50 to 200 mg daily; onychomycosis 200 to 300 mg weekly or 100 to 200 mg every other day (further studies needed).
Oral absorption is rapid/almost complete, so daily dose is the same orally and IV. A loading dose of twice the daily dose on day 1 generally gives near-steady-state concentrations by day 2. For infections other than vaginal candidiasis, choose dose by organism and response; continue until clinical/laboratory activity subsides. Inadequate duration can cause recurrence. AIDS with cryptococcal meningitis or recurrent oral candidiasis usually requires maintenance to prevent relapse.
The reproduced detailed source dosing: oropharyngeal candidiasis 200 mg day 1 then 100 mg daily for at least 2 weeks despite rapid improvement. Esophageal: 200 mg day 1 then 100 mg daily, up to 400 mg/day by clinical judgment; treat at least 3 weeks and at least 2 weeks after symptoms resolve. Optimal systemic Candida dose/duration not established in the cited text; up to 400 mg daily used in small open noncomparative studies. Candida urinary infection/peritonitis: 50 to 200 mg/day used in small open noncomparative studies.
Acute cryptococcal meningitis: 400 mg day 1 then 200 mg daily, possibly 400 mg daily by response. Treat initially for 10 to 12 weeks after CSF cultures become negative. The detailed text specifies AIDS relapse suppression 200 mg daily.
Bone-marrow transplant candidiasis prophylaxis: 400 mg daily. With anticipated severe granulocytopenia (<500 neutrophils/mm3), start several days before anticipated neutropenia and continue for 7 days after count exceeds 1000/mm3.